Acellular Tissue Engineered Vessel
Prescriptionब्रांड नाम: Symvess
About This Medication
11 DESCRIPTION SYMVESS is a sterile, acellular tissue engineered vessel composed of human extracellular matrix (ECM) proteins typically found in human blood vessels. SYMVESS is 6 mm in internal diameter and 42 cm in length (approximately 40 cm of usable length). SYMVESS is manufactured using a tissue engineering process. Human vascular smooth muscle cells that are derived from human aortic tissue deemed suitable for transplant are banked, expanded, and seeded onto a tubular mesh scaffold. The cell-seeded scaffold is cultured in a biomimetic bioreactor system to generate an intermediate tubular construct containing vascular smooth muscle cells and the extracellular matrix the cells deposited. A final decellularization process removes the human cellular and genetic material while maintaining the extracellular matrix structure and mechanical and biological activity. SYMVESS manufacture includes use of reagents derived from human and animal materials. Human male AB serum and fetal bovine serum (FBS) are used in the manufacturing process for the cultivation and expansion of the vascular smooth muscle cells. SYMVESS is fixed inside the packaging bag between the endcaps with a supporting silicone tube and is immersed in sterile phosphate buffered saline solution.
सक्रिय तत्व
| घटक | शक्ति |
|---|---|
| Acellular Tissue Engineered Vessel | - |
संकेत और उपयोग
यह कैसे काम करता है
खुराक और प्रशासन
Side Effects Overview
चेतावनियाँ और सावधानियाँ
5 WARNINGS AND PRECAUTIONS Graft Rupture. ( 5.1 ) Anastomotic Failure. ( 5.2 ) Thrombosis. ( 5.3 ) Transmission of Infectious Diseases ( 5.4 ) 5.1 Graft Rupture Vascular graft rupture has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS [see Dosage and Administration (2) ] . 5.2 Anastomotic Failure Anastomotic failure has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS [see Dosage and Administration (2) ] . 5.3 Thrombosis Thrombosis has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS. 5.4 Transmission of Infectious Diseases SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis ( Treponema pallidum) . The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.
प्रतिनिर्देश
4 CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.
फार्माकोकाइनेटिक्स
Frequently Asked Questions
1 INDICATIONS AND USAGE SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. ( 1 …
2 DOSAGE AND ADMINISTRATION For surgical vascular implantation only. SYMVESS is administered by surgical implantation to replace the injured extremity artery. The anatomical location and length are decided upon at the discretion of the implanting surgeon and based on the appropriate preoperative clinical evaluation, vessel mapping and/or imaging. ( 2.1 ) SYMVESS may be trimmed to provide the length required for each vascular repair. Additionally, a single SYMVESS can be cut into different lengths and used to repair more than …
5 WARNINGS AND PRECAUTIONS Graft Rupture. ( 5.1 ) Anastomotic Failure. ( 5.2 ) Thrombosis. ( 5.3 ) Transmission of Infectious Diseases ( 5.4 ) 5.1 Graft Rupture Vascular graft rupture has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity …
4 CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.
Acellular Tissue Engineered Vessel is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Other Products
Browse all Other products →References & Data Sources
- • DailyMed — Acellular Tissue Engineered Vessel drug label (National Library of Medicine)
- • openFDA — Acellular Tissue Engineered Vessel label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 2700346 (NLM Normalized Drug Names)
- • NDC Directory — Acellular Tissue Engineered Vessel (FDA National Drug Code)
चिकित्सा अस्वीकरण
इस पृष्ठ पर दी गई जानकारी केवल शैक्षणिक उद्देश्यों के लिए है और इसे पेशेवर चिकित्सा सलाह, निदान या उपचार के विकल्प के रूप में उपयोग नहीं किया जाना चाहिए।
किसी चिकित्सा स्थिति या दवा के बारे में आपके किसी भी प्रश्न के लिए हमेशा अपने चिकित्सक या अन्य योग्य स्वास्थ्य सेवा प्रदाता की सलाह लें।
डेटा स्रोत: DailyMed (NLM), openFDA, MFDS